Vaccine
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Ethics review of COVID-19 human challenge studies: A joint HRA/WHO workshop
2022
-
Canadian health care providers' and education workers' hesitance to receive original and bivalent COVID-19 vaccines..
42:126271.
2024
-
Meeting report: Considerations for trial design and endpoints in licensing therapeutic HPV16/18 vaccines to prevent cervical cancer.
42:126100.
2024
-
COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignancies.
42:126074.
2024
-
Revaccination outcomes among adolescents and adults with suspected hypersensitivity reactions following COVID-19 vaccination: A Canadian immunization research network study.
42:126078.
2024
-
COVID-19 vaccine reactogenicity among participants enrolled in the GENCOV study.
42:2733-2739.
2024
-
Thrombosis with thrombocytopenia syndrome (TTS) and vaccine-induced immune thrombocytopenia and thrombosis (VITT): Brighton Collaboration case definitions and guidelines for data collection, analysis, and presentation of immunisation safety data.
42:1799-1811.
2024
-
“I shall not poison my child with your human experiment”: Investigating predictors of parents’ hesitancy about vaccinating younger children (<12) in Canada.
42:505-511.
2024
-
Reactogenicity, pregnancy outcomes, and SARS-CoV-2 infection following COVID-19 vaccination during pregnancy in Canada: A national prospective cohort study.
41:7183-7191.
2023
-
Factors associated with intention for revaccination among patients with adverse events following immunization.
41:6239-6247.
2023
-
Protocol for a living evidence synthesis on variants of concern and COVID-19 vaccine effectiveness.
41:6411-6418.
2023
-
Vaccine Effectiveness of non-adjuvanted and adjuvanted trivalent inactivated influenza vaccines in the prevention of influenza-related hospitalization in older adults: A pooled analysis from the Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN).
41:6359-6365.
2023
-
BNT162b2 mRNA COVID-19 against symptomatic Omicron infection following a mass vaccination campaign in southern Brazil: A prospective test-negative design study.
41:5461-5468.
2023
-
Vaccine-induced immune thrombotic thrombocytopenia after COVID-19 vaccination: Description of a series of 39 cases in Brazil.
40:4788-4795.
2022
-
Effectiveness of the influenza vaccine at reducing adverse events in patients with heart failure: A systematic review and meta-analysis.
40:3433-3443.
2022
-
Extended reporting guidance for vaccine effectiveness studies for variants of concern for COVID-19.
40:2986-2987.
2022
-
Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended spectrum serotype-specific urine antigen detection assay.
40:2635-2646.
2022
-
WHO guidance on COVID-19 vaccine trial designs in the context of authorized COVID-19 vaccines and expanding global access: Ethical considerations.
40:2140-2149.
2022
-
Influenza vaccination uptake among Canadian adults before and during the COVID-19 pandemic: An analysis of the Canadian Longitudinal study on Aging (CLSA).
40:503-511.
2022
-
Adjuvanted trivalent influenza vaccine versus quadrivalent inactivated influenza vaccine in Hutterite Children: A randomized clinical trial.
39:6843-6851.
2021
-
Effect of inactivated influenza vaccination on human coronavirus infection: Secondary analysis of a randomized trial in Hutterite colonies.
39:7058-7065.
2021
-
Key criteria for the ethical acceptability of COVID-19 human challenge studies: Report of a WHO Working Group.
39:633-640.
2021
-
Effectiveness and cost-effectiveness of a Clostridium difficile vaccine candidate in a hospital setting.
38:2585-2591.
2020
-
Impact of quadrivalent HPV vaccine dose spacing on immunologic response in women living with HIV.
38:3073-3078.
2020
-
Evaluating the sensitivity of the bovine BCG challenge model using a prime boost Ad85A vaccine regimen.
38:1241-1248.
2020
-
Diversity of Rotavirus Strains Circulating in Botswana before and after introduction of the Monovalent Rotavirus Vaccine.
37:6324-6328.
2019
-
Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN).
37:5466-5473.
2019
-
Can routinely collected laboratory and health administrative data be used to assess influenza vaccine effectiveness? Assessing the validity of the Flu and Other Respiratory Viruses Research (FOREVER) Cohort.
37:4392-4400.
2019
-
Expressions of pro- and anti-vaccine sentiment on YouTube.
37:2057-2064.
2019
-
A randomized, blinded, placebo-controlled trial comparing antibody responses to homeopathic and conventional vaccines in university students.
36:7423-7429.
2018
-
Reporting and evaluating influenza virus surveillance data: An argument for incidence by single year of age.
36:6249-6252.
2018
-
Does consecutive influenza vaccination reduce protection against influenza: A systematic review and meta-analysis.
36:3434-3444.
2018
-
Examination of the effects of virus inactivation methods on the induction of antibody- and cell-mediated immune responses against whole inactivated H9N2 avian influenza virus vaccines in chickens.
36:3908-3916.
2018
-
Influenza vaccine effectiveness to prevent influenza-related hospitalizations and serious outcomes in Canadian adults over the 2011/12 through 2013/14 influenza seasons: A pooled analysis from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS Network).
36:2166-2175.
2018
-
Preclinical development of peptide vaccination combined with oncolytic MG1-E6E7 for HPV-associated cancer.
36:2181-2192.
2018
-
The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes.
36:313-321.
2018
-
Influenza epidemiology and immunization during pregnancy: Final report of a World Health Organization working group.
35:5738-5750.
2017
-
Burden of vaccine-preventable pneumococcal disease in hospitalized adults: A Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) network study.
35:3647-3654.
2017
-
Corrigendum to “Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age-a phase 3 extension to a randomised controlled trial” [Vaccine 35 (2017) 395–402].
35:3279-3279.
2017
-
Spray dried human and chimpanzee adenoviral-vectored vaccines are thermally stable and immunogenic in vivo.
35:2916-2924.
2017
-
Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age-a phase 3 extension to a randomised controlled trial.
35:395-402.
2017
-
Pregnancy as a risk factor for severe outcomes from influenza virus infection: A systematic review and meta-analysis of observational studies.
35:521-528.
2017
-
HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine.
34:4799-4806.
2016
-
Immunization with chlamydial type III secretion antigens reduces vaginal shedding and prevents fallopian tube pathology following live C. muridarum challenge.
34:3979-3985.
2016
-
Association of serotype with respiratory presentations of pneumococcal infection, Ontario, Canada, 2003–2011.
34:846-853.
2016
-
Randomized evaluation of live attenuated vs. inactivated influenza vaccines in schools (RELATIVES) cluster randomized trial: Pilot results from a household surveillance study to assess direct and indirect protection from influenza vaccination.
33:4910-4915.
2015
-
Developing aerosol vaccines for Mycobacterium tuberculosis: Workshop proceedings.
33:3038-3046.
2015
-
Age-dependent immune responses and immune protection after avian coronavirus vaccination.
33:2655-2661.
2015
-
Randomized evaluation of live attenuated vs. inactivated influenza vaccines in schools (RELATIVES) pilot study: A cluster randomized trial.
33:535-541.
2015
-
Engaging parents and schools improves uptake of the human papillomavirus (HPV) vaccine: Examining the role of the public health nurse.
32:4665-4671.
2014
-
Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release.
32:2882-2895.
2014
-
Toward more specific and transparent research and development costs: The case of seasonal influenza vaccines.
32:3336-3340.
2014
-
Comparison of the immunogenicity and protection against bovine tuberculosis following immunization by BCG-priming and boosting with adenovirus or protein based vaccines.
32:1304-1310.
2014
-
Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995–2011.
31:5863-5871.
2013
-
Immunogenicity comparison of the intradermal or endobronchial boosting of BCG vaccinates with Ad5-85A.
30:6294-6300.
2012
-
Compatibility of ASO3-adjuvanted H1N1pdm09 and seasonal trivalent influenza vaccines in adults: Results of a randomized, controlled trial.
30:4728-4732.
2012
-
Report on the 1st international workshop on procedures for the development of evidence-based vaccination recommendations, Berlin, Germany, 22–23 November 2010.
30:2399-2404.
2012
-
Antibody against Haemophilus influenzae protein D in patients with chronic conditions causing secondary immunodeficiency.
30:1235-1238.
2012
-
Comparison of immune responses and protective efficacy of intranasal prime-boost immunization regimens using adenovirus-based and CpG/HH2 adjuvanted-subunit vaccines against genital Chlamydia muridarum infection.
30:350-360.
2012
-
Comparison of multiple estimates of efficacy for influenza vaccine.
30:1-4.
2011
-
Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC).
29:9171-9176.
2011
-
Acute disseminated encephalomyelitis following influenza vaccination.
29:8182-8185.
2011
-
A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness.
29:1921-1928.
2011
-
Canada's National Advisory Committee on Immunization (NACI): Evidence-based decision-making on vaccines and immunization.
28:A58-A63.
2010
-
Stimulation of anti-polio and anti-HSV IgA pre-plasma cell response in blood following parenteral immunization with tetanus–diphtheria vaccine.
28:1493-1498.
2010
-
On the use of hemagglutination-inhibition for influenza surveillance: Surveillance data are predictive of influenza vaccine effectiveness.
27:2447-2452.
2009
-
Attitudes towards vaccination among chiropractic and naturopathic students.
26:6237-6243.
2008
-
Intranasal and subcutaneous immunization under the effect of estradiol leads to better protection against genital HSV-2 challenge compared to progesterone.
26:6165-6172.
2008
-
The ethics of mandatory vaccination against influenza for health care workers.
26:5562-5566.
2008
-
Influenza vaccination in paediatric nurses: Cross-sectional study of coverage, refusal, and factors in acceptance.
26:2942-2948.
2008
-
Intramuscular immunization with a monogenic plasmid DNA tuberculosis vaccine: Enhanced immunogenicity by electroporation and co-expression of GM-CSF transgene.
25:1342-1352.
2007
-
Influenza vaccination in patients on long-term anticoagulant therapy.
24:6624-6628.
2006
-
The changing epidemiology of chickenpox in Alberta.
23:5398-5403.
2005
-
Semliki Forest virus and Kunjin virus RNA replicons elicit comparable cellular immunity but distinct humoral immunity.
23:4189-4194.
2005
-
Changing attitudes towards polio vaccination: a randomized trial of an evidence-based presentation versus a presentation from a polio survivor.
23:3010-3015.
2005
-
Life-long systemic protection in mice vaccinated with and adenovirus IL-12 vector requires active infection, macrophages and intact lymph nodes.
23:247-257.
2004
-
Continuous antigenic stimulation system (CASS) as a new immunization strategy.
22:3902-3910.
2004
-
The efficacy of electroporated plasmid vaccines correlates with long-term antigen production in vivo.
22:2517-2523.
2004
-
Effect of Vitamin A supplementation on the immune response to measles vaccination.
21:2418-2420.
2003
-
Super-activated interferon-regulatory factors can enhance plasmid immunization.
21:1363-1370.
2003
-
Enhanced immunogenicity of BCG vaccine by using a viral-based GM-CSF transgene adjuvant formulation.
20:2887-2898.
2002
-
Modelling antibody response to measles vaccine and subsequent waning of immunity in a low exposure population.
19:523-529.
2000
-
Development and durability of measles antigen-specific lymphoproliferative response after MMR vaccination.
18:1393-1401.
2000
-
Oral administration of polymer-grafted starch microparticles activates gut-associated lymphocytes and primes mice for a subsequent systemic antigen challenge.
16:2010-2017.
1998
-
Human adenovirus type 5 vectors expressing rabies glycoprotein.
14:1257-1264.
1996
-
Measles, mumps, and rubella antibodies in children 5–6 years after immunization: effect of vaccine type and age at vaccination.
13:1611-1616.
1995
-
Preface.
13:S5-S5.
1995
-
Immunogenicity in mice of tandem repeats of an epitope from herpes simplex gD protein when expressed by recombinant adenovirus vectors.
11:1191-1198.
1993
-
The role of influenza Hemagglutination-Inhibition antibody as a vaccine mediator in children
2024
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)